semaglutide for kidney disease AHA 2024: continues to impress in diabetic Semaglutide in Diabetic Kidney Disease:

Microcirculation (2015) 22(2):13345

Heres what to actually watch for: Common (usually mild): Mild nausea, especially in the first 48 hours after injection Reduced appetite (this is the goal, but can go too far) Fatigue during the first two weeks Constipation or occasional loose stools Injection site irritation Less common but real: Hair thinning, usually tied to rapid weight loss rather than the drug itself Muscle loss if protein intake drops Gallbladder issues in patients with pre-existing risk Mood shifts (both directions have been reported) Serious (rare but require attention): Pancreatitis Severe dehydration Allergic reactions to the compounded formulation Is microdosing semaglutide safe

Patients with gestational diabetes and newly diagnosed T2D had increased levels of serum medium-chain ACs with fewer differences in long-chain ACs levels [44]

This indicates the active ingredient is effectively helping people achieve their weight goals

Personalized Approach: When Genetic Testing Guides Your Treatment Plan Not every patient responds identically to semaglutide or metformin, and genetic variation in peptide pathways significantly influences treatment outcomes